Exemption number (b)(4).On november 28, 2011, the fda granted the permission for the manufacturer fidia farmaceutici spa to submit a single mdr for adverse events that involve medical devices manufactured by fidia farmaceutici spa and imported into the usa by fidia pharma usa, inc.As a consequence, fidia pharmceutici spa (the manufacturer) should submit reportable cases on behalf of (b)(4) (the importer).However, since this is a non-us case of which fidia farmaceutici s.P.A.Has become aware in its role of product manufacturer, fidia pharma usa does not have any reporting obligation.Fidia farmaceutici spa comments: this case lacks sufficient information (e.G.Patient's demographics, complete details of the event, therapy dates and dosages of hyalgan, complete medical and social history, concomitant medications, laboratory/diagnostic results, etc) to make a complete a medical and causal assessment.Moreover, no batch number was received on this complaint, therefore, no investigation can be conducted at the time being.The product is guaranteed as being absolutely sterile.Before distribution, it must pass each of the scheduled chemical, biological and microbiological tests.Moreover, no external contamination can be suspected if the product was stored and handled according to the package instructions.Moreover, no cluster of septic arthritis, possibly indicating a batch contamination, was received at the present time and in the past months.The occasional reports of septic arthritis after hyalgan injections have never been traced back to a contamination of the product itself, but were probably secondary to the injection procedure, the more likely explanation for the occurrence of the event and the reported outcome.As for any other intra-articular therapies, strict aseptic technique is recommended in administering hyalgan.This is the first case of gangrene associated with hyalgan in over 25-years of post-marketing experience.Additional information has been requested and will be provided as soon as it becomes available.
|